Common asthma drug can reduce COVID hospitalizations by 90% — study

A common asthma drug can dramatically reduce hospitalizations, symptoms and recovery time among COVID-19 if taken up to a week after the appearance of symptoms, Oxford University researchers have said according to various reports.

Inhaling the steroid budesonide “reduced the risk of urgent care or hospitalization by 90% when compared with usual care,” the Reuters news agency reports, citing the Oxford experts.

The results were reached after a 28-day study of 146 patients.

“I am heartened that a relatively safe, widely available and well-studied medicine… could have an impact on the pressures we are experiencing during the pandemic,” says researcher Mona Bafadhel, according to Reuters.

Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed